Valeo Pharma (TSE:VPH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Valeo Pharma has reported a record increase in Q2-2024 revenues, reaching $14.1 million, a 4% rise from the previous year, despite a higher adjusted EBITDA loss and a decrease in adjusted gross profit. The pharmaceutical company saw a significant upsurge in prescriptions of its asthma medications, Enerzair and Atectura, which more than doubled over the year. Valeo is undergoing a restructuring to enhance savings and bolster sales growth, setting the stage for a more profitable second half of the year.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.